Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has been given a consensus rating of “Buy” by the seventeen brokerages that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $89.53.
A number of research firms have recently commented on NBIX. Deutsche Bank raised their price objective on shares of Neurocrine Biosciences to $97.00 and gave the stock a “buy” rating in a report on Wednesday. JPMorgan Chase & Co. raised their price objective on shares of Neurocrine Biosciences from $79.00 to $100.00 and gave the stock an “overweight” rating in a report on Wednesday. Barclays reaffirmed an “overweight” rating and set a $100.00 price objective on shares of Neurocrine Biosciences in a report on Wednesday. Oppenheimer set a $100.00 price objective on shares of Neurocrine Biosciences and gave the stock a “buy” rating in a report on Wednesday. Finally, BidaskClub raised shares of Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a report on Wednesday, January 31st.
Neurocrine Biosciences (NASDAQ:NBIX) traded up $1.69 during trading hours on Friday, hitting $85.38. 1,678,433 shares of the stock were exchanged, compared to its average volume of 1,030,000. The company has a market cap of $7,560.00, a P/E ratio of -38.46, a price-to-earnings-growth ratio of 6.41 and a beta of 0.26. Neurocrine Biosciences has a one year low of $39.21 and a one year high of $91.82. The company has a quick ratio of 14.37, a current ratio of 14.38 and a debt-to-equity ratio of 1.05.
In related news, Director William H. Rastetter sold 9,500 shares of the stock in a transaction dated Wednesday, January 24th. The shares were sold at an average price of $90.00, for a total transaction of $855,000.00. Following the completion of the sale, the director now owns 34,250 shares in the company, valued at approximately $3,082,500. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Gary A. Lyons sold 10,000 shares of the stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $72.92, for a total transaction of $729,200.00. Following the sale, the director now owns 272,066 shares of the company’s stock, valued at approximately $19,839,052.72. The disclosure for this sale can be found here. Insiders have sold a total of 337,950 shares of company stock valued at $26,613,876 in the last quarter. 4.80% of the stock is currently owned by corporate insiders.
Several institutional investors have recently made changes to their positions in the stock. First Trust Advisors LP increased its position in Neurocrine Biosciences by 29.0% in the 3rd quarter. First Trust Advisors LP now owns 782,685 shares of the company’s stock valued at $47,963,000 after acquiring an additional 176,136 shares in the last quarter. Janus Henderson Group PLC increased its position in Neurocrine Biosciences by 2.6% in the 3rd quarter. Janus Henderson Group PLC now owns 5,507,763 shares of the company’s stock valued at $337,516,000 after acquiring an additional 140,639 shares in the last quarter. Davidson Kempner Capital Management LP acquired a new stake in Neurocrine Biosciences in the 2nd quarter valued at about $3,639,000. State Street Corp increased its position in Neurocrine Biosciences by 5.1% in the 2nd quarter. State Street Corp now owns 2,710,196 shares of the company’s stock valued at $124,666,000 after acquiring an additional 131,141 shares in the last quarter. Finally, Moody Aldrich Partners LLC increased its position in Neurocrine Biosciences by 13.2% in the 3rd quarter. Moody Aldrich Partners LLC now owns 22,256 shares of the company’s stock valued at $1,364,000 after acquiring an additional 2,591 shares in the last quarter.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.